News stories about Endo International (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Endo International earned a news impact score of 0.11 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.6667285169074 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Endo International plc (ENDP) and Lead Plaintiff Deadline: January 16, 2018 (finance.yahoo.com)
- Reviewing Endo International (ENDP) & RegeneRx Biopharmaceuticals (RGRX) (americanbankingnews.com)
- Financial Survey: Alexza Pharmaceuticals (ALXA) vs. Endo International (ENDP) (americanbankingnews.com)
- Reviewing Endo International (ENDP) and RegeneRx Biopharmaceuticals (RGRX) (americanbankingnews.com)
- Analyzing Endo International (ENDP) & RegeneRx Biopharmaceuticals (RGRX) (americanbankingnews.com)
Several research analysts recently commented on ENDP shares. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Wednesday, October 11th. Mizuho restated a “buy” rating and set a $14.00 price target (down previously from $19.00) on shares of Endo International in a research note on Tuesday, September 12th. Royal Bank Of Canada cut their price target on shares of Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. ValuEngine lowered shares of Endo International from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Goldman Sachs Group started coverage on shares of Endo International in a research note on Thursday, September 28th. They set a “sell” rating and a $7.00 price target on the stock. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company’s stock. Endo International has a consensus rating of “Hold” and a consensus price target of $11.67.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. Endo International had a negative net margin of 126.97% and a positive return on equity of 66.98%. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.01 earnings per share. research analysts forecast that Endo International will post 3.67 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://stocknewstimes.com/2017/12/06/endo-international-endp-earning-somewhat-positive-press-coverage-analysis-shows.html.
About Endo International
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.